Qi Zhou: Clinical Trials

2 unknown, 1 active not recruiting, 1 not yet recruiting. 2 Phase 1, 1 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	2	Active not recruiting 1, Unknown 1
Phase 2	1	Unknown 1

Follow Qi Zhou: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Non-interventional Registration Study of Monotherapy or Combination Regimens Based on Camrelizumab or Famitinib for the Treatment of Cervical Cancer Camrelizumab, Famitinib - Cervical Cancer Metastatic, Cervical Cancer Recurrent		Not yet recruiting	Qi Zhou	1300	2025-12-30	2025-12-05
A Study to Evaluate Dual mTORC1/2 Inhibitor (ATG 008) or Selective Inhibitor of Nuclear Export Compound (ATG-010) in Combination With Chemotherapy in Patients With Relapsed or Metastatic Ovarian Cancer, Endometrial Cancer, and Cervical Cancer ( PORCH ) ATG-008, ATG-010 - 1. Relapsed Ovarian Cancer 2. Metastatic Ovarian Cancer 3. Endometrial Cancer 4. Cervical Cancer	Phase 2	Unknown	Qi Zhou	96	2021-08-03	2021-08-10
Safety and Efficacy of Subretinal Transplantation of Clinical Human Embryonic Stem Cell Derived Retinal Pigment Epitheliums in Treatment of Retinitis Pigmentosa Retinal pigment epitheliums transplantation - Retinitis Pigmentosa	Phase 1	Active not recruiting	Qi Zhou	25	2021-05-19	2026-07-06
Clinical Safety Study of Human Embryonic Stem Cell Derived Mesenchymal Cells in the Treatment of Moderate and Severe Intrauterine Adhesions Inject a solution of stem cell preparation, Inject stem cells - Intrauterine Adhesion	Phase 1	Unknown	Qi Zhou	32	2020-01-01	2020-01-18

Conditions studied

Endometrial Neoplasms (1)  ·  Gynatresia (1)  ·  Ovarian Neoplasms (1)  ·  Retinitis Pigmentosa (1)  ·  Uterine Cervical Neoplasms (1)

Interventions

camrelizumab (1)  ·  famitinib (1)

Countries

China (2)

Top investigators

Zhou Qi, Doctor (1)